Indaptus shares surge 13.79% intraday after positive safety data in Decoy20 trial and $2.3M fundraising.

Indaptus Therapeutics surged 13.79% intraday following its Q3 2025 earnings report and corporate update. The stock’s rally was driven by two key factors: (1) positive safety data from the Safety Lead-In cohort in its Decoy20 and tislelizumab combination trial, where the treatment was deemed tolerable at current dosing, and (2) a $2.3 million fundraising via an at-the-market facility in September 2025, strengthening its balance sheet. While enrollment in the trial was paused pending further efficacy evaluations, the safety results and improved liquidity bolstered investor confidence. Additionally, the company’s Q3 loss per share narrowed to -$2.98, exceeding analyst estimates of -$4.17, signaling better-than-expected cost management despite increased R&D spending. These developments collectively positioned Indaptus as a speculative play on potential clinical progress and financial stability.